Table 3.

Prescription claims generic drugs prices, US commercial health plans 2008–2013 [38].

Monopoly generic market	+ 47.4% (CI, 25.4% to 73.2%)
Near-monopoly generic market	+ 20.1% (CI, 5.5% to 36.6%)
Two generic companies	−11.8% (CI, −18.6% to −4.4%)
Four generic companies	−31.7% (95% CI, −34.4% to −28.9%)

+ increase in price; – decrease in price; CI = confidence interval.